Table 2—

Effect of omalizumab on exacerbation rates across studies

Study/first author [Ref.]	Annual exacerbation rate treatment difference	Reduction %	p-value
INNOVATE study [1]	0.49	26.2^#	0.042^#
ETOPA study [10]	1.49	60.4	<0.001
SOLAR study [8]	0.29	37.5	0.027
Busse [7]	0.40	40.3	<0.001
Solèr [4]	0.70	57.6	<0.001
Holgate [9]	0.42	26.5	0.165
ALTO study [11]	0.18	15.3	0.077
Pooled [3]	0.56	38.3	<0.0001

^#: values differ slightly from those reported by Humbert et al. [1] due to differences in the method used for grouping centres. Data taken from [3].